Merck KGaA Fertility Business And Mavenclad Held Back By COVID-19 But Recovery Signs
Candidate Anti-COVID Toll-like Receptor Inhibitor Starts Phase II
Executive Summary
Merck KGaA’s pharmaceutical sales were adversely affected by the COVID-19 pandemic in the second quarter, but the Process Solutions part of its life sciences division, products from which support vaccine developers, had a good quarter, and a potential dual Toll-like receptor inhibitor, M5049, entered Phase II.
You may also be interested in...
Pipeline Watch: Phase III Starts In PAH, NSCLC And Seizure Disorders
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Denmark's IO Vaccine Biotech Attracts Investor Interest
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
Need a specific report? 1000+ reports available
Buy Reports